C26-A6

Key Product Details

Product Description

C26-A2 inhibits the interaction between MTDH and SND1 by blocking the SND1 pocket. C26-A2 disrupts MTDH-SND1 complex-induced reduction in tumor antigen presentation and T cell infiltration; enhancing immune surveillance and sensitivity to anti-PD-1 therapy in metastatic breast cancer mouse models. C26-A6 suppresses tumor growth (IC₅₀ = 12.3 μM) and metastasis and enhances chemotherapy sensitivity in triple-negative breast cancer (TNBC) mouse models.

Product Specifications for C26-A6

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for C26-A6

The following data is based on the product molecular weight 352.79.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.83 mL	14.17 mL	28.35 mL
5 mM	0.57 mL	2.83 mL	5.67 mL
10 mM	0.28 mL	1.42 mL	2.83 mL
50 mM	0.06 mL	0.28 mL	0.57 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Shen Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat.Cancer 2022 PMID: 35121988
• Shen Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis. Nat.Cancer 2022 PMID: 35121987

Product Documents for C26-A6